BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders

Core Insights - BetterLife Pharma Inc. is focused on developing BETR-001, a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders [1][10] - BETR-001 has shown promising preclinical data, particularly in animal models for depression and anxiety, by selectively activating the 5HT2A receptor without inducing hallucinations [2][3][6] Group 1: BETR-001 Mechanism and Efficacy - BETR-001 activates the 5HT2A receptor to a maximum of 60%, which is below the 70% threshold that typically leads to hallucinations, unlike other substances such as LSD that activate it near 90% [3][6] - The compound's mechanism allows for a therapeutic effect without the side effects associated with traditional treatments, which often involve reuptake inhibitors [2][3] Group 2: Development and Regulatory Status - BetterLife has received a composition of matter patent for BETR-001 from the USPTO and has completed most of the required IND-enabling studies [7][8] - The company plans to file for IND and begin human trials in the first half of 2026, with potential applications for various psychiatric and neurological disorders [8] Group 3: Competitive Advantages - BETR-001 does not activate the 5HT2B receptor, which is linked to cardiac safety, providing an advantage over other agents like LSD and psilocybin [6] - The compound does not induce tolerance with repeated dosing, allowing for daily administration if necessary, and it is classified as a non-controlled substance, enabling patient self-administration [6][10]